Skip to main content
Clinical Trials/NCT04982341
NCT04982341
Completed
Not Applicable

Effectiveness of High-flow Nasal Cannula and Prone Positioning in Awake Patients With COVID-19 and Severe Acute Respiratory Failure

Hôpital Universitaire Fattouma Bourguiba1 site in 1 country120 target enrollmentSeptember 2, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hypoxemic Respiratory Failure
Sponsor
Hôpital Universitaire Fattouma Bourguiba
Enrollment
120
Locations
1
Primary Endpoint
Number of patients without intubation
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The investigators evaluate the effects of High-flow nasal cannula (HFNC) in association with prone in patients with Covid-19 severe ARF.

Detailed Description

The investigators evaluate the effects of High-flow nasal cannula (HFNC) in association with prone in patients with Covid-19 severe ARF. All patients with ARF related to Covid-19 and admitted to the ICU are turned in prone position whenever tolerated, while receiving oxygenation with HFNC. Outcomes of interest are the rate of success or failure (defined as the need for intubation and mechanical ventilation)

Registry
clinicaltrials.gov
Start Date
September 2, 2020
End Date
March 3, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Hôpital Universitaire Fattouma Bourguiba
Responsible Party
Principal Investigator
Principal Investigator

Fekri Abroug

Professor Head of the ICU

Hôpital Universitaire Fattouma Bourguiba

Eligibility Criteria

Inclusion Criteria

  • aged ≥18 years, admitted to the medical ICU for confirmed Covid-19 and acute hypoxemic respiratory failure

Exclusion Criteria

  • patients already intubated at admission or those requiring immediate intubation

Outcomes

Primary Outcomes

Number of patients without intubation

Time Frame: through study completion, an average of 28 days

successful oxygenation without intubation

Study Sites (1)

Loading locations...

Similar Trials